A First-in-Human, Open-label, Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancers

Trial Profile

A First-in-Human, Open-label, Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancers

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs JNJ 63723283 (Primary)
  • Indications Bladder cancer; Colorectal cancer; Gastric cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Renal cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 06 Dec 2017 Planned End Date changed from 18 Jul 2019 to 26 Jul 2019.
    • 02 Nov 2017 Planned number of patients changed from 169 to 229.
    • 03 Feb 2017 Planned End Date changed from 1 Apr 2019 to 1 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top